Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Completed · Phase 2 · NCT06593600
Conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
At a glance
- Research payments reported, 2025
- $1.9M
- U.S. investigators named
- 17
- Sites paid
- 16
- Planned or actual enrollment
- 82
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN7544 (drug), Placebo (drug)
- Dates
- Started 2024-11-13; completion 2026-07-08
- Results posted
- Not yet
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects symptoms associated with POTS
From ClinicalTrials.gov, last updated 2026-07-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $1.9M in research payments for this study in 2025 (577 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rachel Bond, M.D. Cardiology · Gilbert, AZ
- Brent P. Goodman, M.D. Neurology · Scottsdale, AZ
- Gregory M. Giesler, MD Cardiology · Pasadena, CA
- Mitchell G. Miglis, MD Neurology · Stanford, CA
- Gregory A. Sahagian, M.D. Neurology · Carlsbad, CA
- Jeffrey Turner, M.D. Nephrology (Kidney) · New Haven, CT
- Miguel E. Trevino, MD PA Internal Medicine · Clearwater, FL
- Alexandru C. Barboi, MD Neurology · Indianapolis, IN
- Roy L. Freeman, M.D. Neurology · Boston, MA
- John J. Lee, M.D. Allergy & Immunology · Boston, MA
- Guillaume J. Lamotte, M.D. Neurology · Rochester, MN
- Wolfgang Singer, M.D. Neurology · Rochester, MN
- Thomas H. Brannagan III, MD Neurology · New York, NY
- Alejandra Gonzalez-duarte General Practice · New York, NY
- Stavros Stavrakis, MD Cardiology · Oklahoma City, OK
- Italo Biaggioni, MD Clinical Pharmacology · Nashville, TN
- Steven A. Vernino, MD PHD Neurology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Profound Research LLC $494,481
- Vanderbilt University Medical Center, TN $168,223
- Yale University $166,143
- Chandler Regional Medical Center, AZ $148,788
- University of Texas Southwestern Medical Center $117,932
- Board of the Leland Stanford $117,910
- Innovative Research of West Florida Inc $105,007
- University of Utah Hospital and Clinics, UT $104,823
- Board of Regents of the University of Oklahoma Health Sciences Center $84,676
- Indiana University $78,745
- Beth Israel Deaconess Medical Center, MA $75,350
- New York University School of Medicine $65,334
- Mayo Clinic $49,261
- Trustees of Columbia University in The City of New York $26,288
- St Lukes Hospital of Kansas City, MO $25,950
- Metrodora Clinic PLLC $14,200
- $9,931
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.